HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
1 - 10 of 189
Healthy Children Needed for Single Study Visit on Immunometabolic Dysregulation
Healthy control children are needed to help participate in a study on Immunometabolic Dysregulation.
Sleep and Growth Study 2
The Children’s Hospital of Philadelphia is seeking healthy adolescents between the ages of 12-13, who are currently in the 7th grade, to participate in the Sleep and Growth Study 2.
Pediatric Normative Data for the Complete Minnesota Dexterity Test
The Division of Rheumatology at CHOP is looking to engage healthy participants for several research studies with the goal of learning more about ways to improve the health and well-being of children and young adults.
Glomerular disease is a major cause of chronic kidney disease associated with substantial morbidity; children and adults with glomerular disease face many threats to bone health.
16BT052; Unrelated And Partially Matched Related Donor PSCT w/ TCR αβ depletion for patients with BMF
The purpose of this research study is to test a new method of cell processing for stem cell transplants with an unrelated donor or partially matched related donor for patients with BMF who do not have a well matched related donor.
The purpose of this research study is to understand the impact of transplant on the quality of life of the entire family including sibling donors, other siblings and parents.
A Study to Evaluate the Safety andEfficacy of a Single Dose of CTX001 in Subjects With Severe Sickle Cell Disease
The purpose of this research study is to learn more about the safety and effects of CTX001 (the “Study Product”) in patients ages 12 to 35 years who have been diagnosed with severe sickle cell disease.
AA Genetic Study
The purpose of this study is to compare the genes of African American children and adults who have inflammatory bowel disease (IBD) with the genes of those who do not have IBD.
AALL1131; A Phase 3 Randomized Trial for HR B-ALL with Dasatinib Arm in Ph-like TKI Sensitive Mutations
The study compares 2 different experimental chemotherapy combinations with the usual chemotherapy combination given during post-Induction therapy.
AALL1521; Ruxolitinib and Chemotherapy for Patients with JAK-Mutant B-ALL
This study is testing the safety and effectiveness of adding a targeted therapy (ruxolitinib) to standard chemotherapy for children, adolescents, and young adults with high-risk acute lymphoblastic leukemia with CRLF2 and other JAK pathway mutations.